JP5697123B2 - 酸性化ポリエチレンイミンを用いる細胞への核酸導入方法 - Google Patents

酸性化ポリエチレンイミンを用いる細胞への核酸導入方法 Download PDF

Info

Publication number
JP5697123B2
JP5697123B2 JP2009174234A JP2009174234A JP5697123B2 JP 5697123 B2 JP5697123 B2 JP 5697123B2 JP 2009174234 A JP2009174234 A JP 2009174234A JP 2009174234 A JP2009174234 A JP 2009174234A JP 5697123 B2 JP5697123 B2 JP 5697123B2
Authority
JP
Japan
Prior art keywords
pei
cells
nucleic acid
transfection
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009174234A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011024493A (ja
JP2011024493A5 (enExample
Inventor
直人 山口
直人 山口
泰典 福本
泰典 福本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiba University NUC
Original Assignee
Chiba University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiba University NUC filed Critical Chiba University NUC
Priority to JP2009174234A priority Critical patent/JP5697123B2/ja
Priority to US12/752,188 priority patent/US8507270B2/en
Publication of JP2011024493A publication Critical patent/JP2011024493A/ja
Publication of JP2011024493A5 publication Critical patent/JP2011024493A5/ja
Priority to US13/936,259 priority patent/US9249417B2/en
Application granted granted Critical
Publication of JP5697123B2 publication Critical patent/JP5697123B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009174234A 2009-07-27 2009-07-27 酸性化ポリエチレンイミンを用いる細胞への核酸導入方法 Expired - Fee Related JP5697123B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009174234A JP5697123B2 (ja) 2009-07-27 2009-07-27 酸性化ポリエチレンイミンを用いる細胞への核酸導入方法
US12/752,188 US8507270B2 (en) 2009-07-27 2010-04-01 Method of transfecting cells with nucleic acids using acidified polyethylenimine
US13/936,259 US9249417B2 (en) 2009-07-27 2013-07-08 Reagent kit having acidified polvethvlendimine for introducting nucleic acids into cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009174234A JP5697123B2 (ja) 2009-07-27 2009-07-27 酸性化ポリエチレンイミンを用いる細胞への核酸導入方法

Publications (3)

Publication Number Publication Date
JP2011024493A JP2011024493A (ja) 2011-02-10
JP2011024493A5 JP2011024493A5 (enExample) 2012-09-13
JP5697123B2 true JP5697123B2 (ja) 2015-04-08

Family

ID=43497651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009174234A Expired - Fee Related JP5697123B2 (ja) 2009-07-27 2009-07-27 酸性化ポリエチレンイミンを用いる細胞への核酸導入方法

Country Status (2)

Country Link
US (2) US8507270B2 (enExample)
JP (1) JP5697123B2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5697123B2 (ja) 2009-07-27 2015-04-08 国立大学法人 千葉大学 酸性化ポリエチレンイミンを用いる細胞への核酸導入方法
EP2338520A1 (de) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung
US10881682B2 (en) 2015-08-26 2021-01-05 International Business Machines Corporation Therapeutic compositions comprising n-alkyl-hydroxy polymers
WO2017197471A1 (pt) * 2016-05-19 2017-11-23 Universidade Estadual De Campinas - Unicamp Kit x-pei e método de transfecção celular
EP3510161A4 (en) 2016-08-23 2020-04-22 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING DEFICIENCY IN A HUMAN SUBJECT
WO2018100089A1 (en) 2016-12-01 2018-06-07 Norbert Gretz Means and methods for visualization of tissue structures
CN106943015A (zh) * 2017-03-29 2017-07-14 广西喜爱家饮水设备有限公司 自动化饮水系统
BR112019025792A2 (pt) 2017-06-07 2020-07-07 Spark Therapeutics, Inc. agentes de aperfeiçoamento para transfecção de células melhoradas e/ou produção de vetor raav
JP7333930B2 (ja) * 2019-01-07 2023-08-28 独立行政法人国立高等専門学校機構 ミミズ細胞の保存方法及びミミズ培養細胞の形質転換方法
WO2021168362A1 (en) 2020-02-21 2021-08-26 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
DE102020114183B4 (de) 2020-05-27 2022-07-14 Universität Leipzig Dezernat Forschung und Transfer Mittel zur transfektion von nukleinsäuren in zellen
CN112695056A (zh) * 2020-12-29 2021-04-23 苏州汇桢生物技术有限公司 一种提高瞬时转染效率的转染试剂及转染方法
CN114561413B (zh) * 2022-03-24 2023-09-29 新乡医学院 一种瞬时转染试剂及其应用
EP4578952A1 (en) 2022-08-22 2025-07-02 FUJIFILM Corporation Method for introducing nucleic acid into cells and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3996028B2 (ja) * 2002-09-30 2007-10-24 株式会社日本触媒 蛋白質又はペプチドの細胞内導入方法
CN1989213B (zh) * 2004-07-28 2010-08-04 大日本油墨化学工业株式会社 有机无机复合涂膜及水性涂料组合物
JP5697123B2 (ja) 2009-07-27 2015-04-08 国立大学法人 千葉大学 酸性化ポリエチレンイミンを用いる細胞への核酸導入方法

Also Published As

Publication number Publication date
US9249417B2 (en) 2016-02-02
US20130292606A1 (en) 2013-11-07
JP2011024493A (ja) 2011-02-10
US8507270B2 (en) 2013-08-13
US20110020927A1 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
JP5697123B2 (ja) 酸性化ポリエチレンイミンを用いる細胞への核酸導入方法
Bono et al. Non-viral in vitro gene delivery: it is now time to set the bar!
Kurosaki et al. Ternary complexes of pDNA, polyethylenimine, and γ-polyglutamic acid for gene delivery systems
Debus et al. Delivery of messenger RNA using poly (ethylene imine)–poly (ethylene glycol)-copolymer blends for polyplex formation: Biophysical characterization and in vitro transfection properties
Jain et al. Comparison of avidin, neutravidin, and streptavidin as nanocarriers for efficient siRNA delivery
Fukumoto et al. Cost-effective gene transfection by DNA compaction at pH 4.0 using acidified, long shelf-life polyethylenimine
Liang et al. Self-assembled ternary complexes stabilized with hyaluronic acid-green tea catechin conjugates for targeted gene delivery
Benoit et al. Controlling mesenchymal stem cell gene expression using polymer-mediated delivery of siRNA
Sun et al. Synthesis and evaluation of pH-sensitive multifunctional lipids for efficient delivery of CRISPR/Cas9 in gene editing
Shi et al. Developing a chitosan supported imidazole Schiff-base for high-efficiency gene delivery
Ewe et al. Polymeric nanoparticles based on tyrosine-modified, low molecular weight polyethylenimines for siRNA delivery
Mady et al. Effect of polymer molecular weight on the DNA/PEI polyplexes properties
US20120295355A1 (en) Nucleic acid delivery using modified chitosans
JP2018502956A (ja) 核酸を細胞内へ導入するための組成物
CN103255174A (zh) 以聚乙二醇接枝的透明质酸为外层的三元复合物及三元复合物的液体与应用
JP2011505826A5 (enExample)
Ihm et al. Improved biocompatibility of polyethylenimine (PEI) as a gene carrier by conjugating urocanic acid: In vitro and in vivo
US20230218536A1 (en) Nanoparticles containing complexes of nucleic acids and cationic copolymers, process for preparing them and their use for gene transfer in cells
Chen et al. Bioengineering a non-genotoxic vector for genetic modification of mesenchymal stem cells
CN108113961B (zh) 亚精胺三盐酸盐介导核酸纳米材料自组装方法及采用该方法制备的三棱柱的纳米制剂和应用
Roustazadeh et al. Enhancing non-viral gene delivery to human T cells through tuning nanoparticles physicochemical features, modulation cellular physiology, and refining transfection strategies
Alkan et al. A Cationic Stearamide‐based Solid Lipid Nanoparticle for Delivering Yamanaka Factors: Evaluation of the Transfection Efficiency
US11554173B2 (en) Methods of transfection for large cargo using poly(beta-amino esters)
He et al. A novel gene carrier based on amino-modified silica nanoparticles
EP4600356A1 (en) Method for introducing nucleic acid into mitochondrion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150205

R150 Certificate of patent or registration of utility model

Ref document number: 5697123

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees